Trial Profile

EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Bladder cancer; Carcinoma
Focus Therapeutic Use
Acronyms ATEZOBLADDERPRESERVE

Most Recent Events

04 Jun 2024 Interim results (n=59) evaluating the efficacy and safety of atezolizumab (ATZ) concurrent with external beam RT (EBRT) for muscle-invasive bladder cancer (MIBC) treatment as bladder preservation therapy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
25 Oct 2022 Status changed from recruiting to active, no longer recruiting.
07 Jun 2022 Interim results (n=26) presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com